Dammarenediol II

Dammarenediol II is a tetracyclic triterpenoid alcohol that serves as the central precursor in the biosynthesis of ginsenosides, the primary bioactive compounds in Panax ginseng. It is enzymatically hydroxylated by the cytochrome P450 enzyme CYP716A47 to form protopanaxadiol, initiating the downstream production of pharmaceutically relevant ginsenosides.

Origin & History

Dammarenediol II is a tetracyclic triterpenoid (dammarane-type) with molecular formula C₃₀H₅₂O₂ produced in plants like Panax ginseng (ginseng) and Gynostemma pentaphyllum through enzymatic cyclization of 2,3-oxidosqualene by dammarenediol-II synthase (DDS). It serves as a key biosynthetic precursor to ginsenosides and gypenosides, and can be extracted from natural sources or synthesized in engineered yeast systems.

Historical & Cultural Context

No historical or traditional medicinal uses are documented for isolated Dammarenediol II. While it functions as a biosynthetic intermediate in Panax ginseng (used in Traditional Chinese Medicine for vitality), the compound itself has no traditional therapeutic references.

Health Benefits

• No direct health benefits established - research limited to biosynthetic pathway studies
• Functions as precursor to ginsenosides (evidence quality: preliminary - in vitro only)
• Converted to protopanaxadiol by CYP716A47 enzyme in biosynthesis (evidence quality: preliminary - yeast expression systems)
• Part of triterpene saponin production pathway (evidence quality: preliminary - plant metabolomic studies)
• No human clinical trials or therapeutic applications documented (evidence quality: none)

How It Works

Dammarenediol II is synthesized from 2,3-oxidosqualene via a two-step cyclization catalyzed by dammarenediol II synthase (DDS), a member of the oxidosqualene cyclase family. The resulting tetracyclic scaffold is then regiospecifically hydroxylated at the C-12 position by the cytochrome P450 monooxygenase CYP716A47, yielding protopanaxadiol. Protopanaxadiol subsequently undergoes further hydroxylation by CYP716A53v2 to form protopanaxatriol, which serves as the aglycone backbone for a broad class of ginsenosides including Rb1, Rg1, and Re.

Scientific Research

No human clinical trials, randomized controlled trials (RCTs), or meta-analyses have been conducted on Dammarenediol II. All available research consists of in vitro enzymatic assays, yeast expression systems, and plant metabolomic/transcriptomic studies examining its role in biosynthesis, with no PMIDs referencing human outcome studies.

Clinical Summary

No human clinical trials have investigated dammarenediol II directly, as research has been confined to in vitro biochemical characterization and heterologous expression studies in yeast systems such as Saccharomyces cerevisiae. Studies reconstructing the ginsenoside biosynthetic pathway in engineered yeast have confirmed dammarenediol II's obligate role as a pathway intermediate, but these findings do not translate directly to human pharmacological activity. Its biological relevance in humans is currently inferred entirely from the well-documented clinical literature on downstream ginsenosides, not from any independent efficacy data. The evidence base for dammarenediol II itself must be classified as preliminary and mechanistic only.

Nutritional Profile

Dammarenediol II is a tetracyclic triterpenoid compound (molecular formula C30H52O2, molecular weight 448.73 g/mol) and is not a nutritional ingredient in the conventional sense - it contains no meaningful macronutrients, micronutrients, vitamins, minerals, fiber, or protein. As a pure biosynthetic intermediate compound, it is a steroidal-type alcohol belonging to the dammarane-type triterpene class. It possesses two hydroxyl groups at C-3 and C-20 positions, which are the functional sites for subsequent enzymatic modifications. Concentrations in Panax ginseng root tissue are extremely low (estimated trace quantities in the nanogram-to-microgram per gram dry weight range), as it exists transiently as a metabolic intermediate rather than accumulating as a stable end product. Its bioavailability as an isolated compound is expected to be poor due to its highly lipophilic nature (high logP estimated >7), limiting aqueous solubility to approximately <1 mg/mL. It is synthesized from 2,3-oxidosqualene via the enzyme dammarenediol synthase (DS) and serves exclusively as a committed precursor in the ginsenoside biosynthetic pathway. No caloric value, dietary reference intake, or nutritional significance has been established for this compound.

Preparation & Dosage

No clinically studied dosage ranges exist for Dammarenediol II as it lacks human clinical data. The compound is used only in microgram-to-milligram quantities for in vitro enzymatic research assays. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Not applicable - research compound only

Safety & Interactions

No human safety data, toxicology studies, or adverse event reports exist specifically for isolated dammarenediol II, as it is not commercially available as a standalone supplement. Because it is an endogenous biosynthetic intermediate rather than a final bioactive compound, direct human exposure through supplementation is not currently a practical consideration. Any safety assumptions should be derived cautiously from the broader triterpenoid and ginsenoside literature, which identifies potential interactions with anticoagulants, hypoglycemic agents, and immunosuppressants. Pregnant or nursing individuals should avoid speculative supplementation with any ginseng-derived triterpenoids, including precursors, until dedicated safety data are available.